Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma

G. N. Hortobagyi, T. L. Smith, K. D. Swenerton, S. S. Legha, A. U. Buzdar, G. R. Blumenschein, J. U. Gutterman, Evan M Hersh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Two hundred patients with metastatic breast cancer who were treated with combination chemotherapy and nonspecific immunotherapy with BCG or MER were skin tested prior to, and at regular intervals during the administration of chemotherapy with a battery of 6 antigens (Dermatophytin, Varidase, candida, mumps, PPD, and KLH). Delayed-type hypersensitivity responses to this battery of antigens were analyzed to assess whether they correlated with ability to respond to chemotherapy, length of survival, and a number of other host and tumor characteristics of known prognostic significance. Responsiveness to individual recall antigens or the number of positive skin test responses did not correlate with overall or complete response rates. This correlation did exist with KLH, a primary antigen. A positive response to 2 or more antigens correlated with a longer survival. Inability to mount a skin test response to any antigen correlated with poor survival. PPD conversions during serial BCG administration did not correlate with a better prognosis. Serial skin testing with a battery of antigens did not correlate with prognosis. Skin test responsiveness to the antigens used in this study did not correlate with other pretreatment factors of prognostic importance such as tumor burden, absolute lymphocyte count, performance status, prior radiation therapy, menopausal status, and age. Therefore, responsiveness to skin testing with these antigens appears to be an independent prognostic variable and should be incorporated in the planning and analysis of systemic treatment programs in metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)1369-1376
Number of pages8
JournalCancer
Volume47
Issue number6
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Skin Tests
Breast Neoplasms
Antigens
methanol extraction residue (MER) tubercle bacillus fraction
Tuberculin
Skin
Survival
Streptodornase and Streptokinase
Drug Therapy
Mumps
Delayed Hypersensitivity
Lymphocyte Count
Mycobacterium bovis
Combination Drug Therapy
Tumor Burden
Candida
Immunotherapy
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. / Hortobagyi, G. N.; Smith, T. L.; Swenerton, K. D.; Legha, S. S.; Buzdar, A. U.; Blumenschein, G. R.; Gutterman, J. U.; Hersh, Evan M.

In: Cancer, Vol. 47, No. 6, 1981, p. 1369-1376.

Research output: Contribution to journalArticle

Hortobagyi, GN, Smith, TL, Swenerton, KD, Legha, SS, Buzdar, AU, Blumenschein, GR, Gutterman, JU & Hersh, EM 1981, 'Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma', Cancer, vol. 47, no. 6, pp. 1369-1376. https://doi.org/10.1002/1097-0142(19810315)47:6<1369::AID-CNCR2820470622>3.0.CO;2-3
Hortobagyi, G. N. ; Smith, T. L. ; Swenerton, K. D. ; Legha, S. S. ; Buzdar, A. U. ; Blumenschein, G. R. ; Gutterman, J. U. ; Hersh, Evan M. / Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. In: Cancer. 1981 ; Vol. 47, No. 6. pp. 1369-1376.
@article{792812c30c2144ad83922f282c431d38,
title = "Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma",
abstract = "Two hundred patients with metastatic breast cancer who were treated with combination chemotherapy and nonspecific immunotherapy with BCG or MER were skin tested prior to, and at regular intervals during the administration of chemotherapy with a battery of 6 antigens (Dermatophytin, Varidase, candida, mumps, PPD, and KLH). Delayed-type hypersensitivity responses to this battery of antigens were analyzed to assess whether they correlated with ability to respond to chemotherapy, length of survival, and a number of other host and tumor characteristics of known prognostic significance. Responsiveness to individual recall antigens or the number of positive skin test responses did not correlate with overall or complete response rates. This correlation did exist with KLH, a primary antigen. A positive response to 2 or more antigens correlated with a longer survival. Inability to mount a skin test response to any antigen correlated with poor survival. PPD conversions during serial BCG administration did not correlate with a better prognosis. Serial skin testing with a battery of antigens did not correlate with prognosis. Skin test responsiveness to the antigens used in this study did not correlate with other pretreatment factors of prognostic importance such as tumor burden, absolute lymphocyte count, performance status, prior radiation therapy, menopausal status, and age. Therefore, responsiveness to skin testing with these antigens appears to be an independent prognostic variable and should be incorporated in the planning and analysis of systemic treatment programs in metastatic breast cancer.",
author = "Hortobagyi, {G. N.} and Smith, {T. L.} and Swenerton, {K. D.} and Legha, {S. S.} and Buzdar, {A. U.} and Blumenschein, {G. R.} and Gutterman, {J. U.} and Hersh, {Evan M}",
year = "1981",
doi = "10.1002/1097-0142(19810315)47:6<1369::AID-CNCR2820470622>3.0.CO;2-3",
language = "English (US)",
volume = "47",
pages = "1369--1376",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma

AU - Hortobagyi, G. N.

AU - Smith, T. L.

AU - Swenerton, K. D.

AU - Legha, S. S.

AU - Buzdar, A. U.

AU - Blumenschein, G. R.

AU - Gutterman, J. U.

AU - Hersh, Evan M

PY - 1981

Y1 - 1981

N2 - Two hundred patients with metastatic breast cancer who were treated with combination chemotherapy and nonspecific immunotherapy with BCG or MER were skin tested prior to, and at regular intervals during the administration of chemotherapy with a battery of 6 antigens (Dermatophytin, Varidase, candida, mumps, PPD, and KLH). Delayed-type hypersensitivity responses to this battery of antigens were analyzed to assess whether they correlated with ability to respond to chemotherapy, length of survival, and a number of other host and tumor characteristics of known prognostic significance. Responsiveness to individual recall antigens or the number of positive skin test responses did not correlate with overall or complete response rates. This correlation did exist with KLH, a primary antigen. A positive response to 2 or more antigens correlated with a longer survival. Inability to mount a skin test response to any antigen correlated with poor survival. PPD conversions during serial BCG administration did not correlate with a better prognosis. Serial skin testing with a battery of antigens did not correlate with prognosis. Skin test responsiveness to the antigens used in this study did not correlate with other pretreatment factors of prognostic importance such as tumor burden, absolute lymphocyte count, performance status, prior radiation therapy, menopausal status, and age. Therefore, responsiveness to skin testing with these antigens appears to be an independent prognostic variable and should be incorporated in the planning and analysis of systemic treatment programs in metastatic breast cancer.

AB - Two hundred patients with metastatic breast cancer who were treated with combination chemotherapy and nonspecific immunotherapy with BCG or MER were skin tested prior to, and at regular intervals during the administration of chemotherapy with a battery of 6 antigens (Dermatophytin, Varidase, candida, mumps, PPD, and KLH). Delayed-type hypersensitivity responses to this battery of antigens were analyzed to assess whether they correlated with ability to respond to chemotherapy, length of survival, and a number of other host and tumor characteristics of known prognostic significance. Responsiveness to individual recall antigens or the number of positive skin test responses did not correlate with overall or complete response rates. This correlation did exist with KLH, a primary antigen. A positive response to 2 or more antigens correlated with a longer survival. Inability to mount a skin test response to any antigen correlated with poor survival. PPD conversions during serial BCG administration did not correlate with a better prognosis. Serial skin testing with a battery of antigens did not correlate with prognosis. Skin test responsiveness to the antigens used in this study did not correlate with other pretreatment factors of prognostic importance such as tumor burden, absolute lymphocyte count, performance status, prior radiation therapy, menopausal status, and age. Therefore, responsiveness to skin testing with these antigens appears to be an independent prognostic variable and should be incorporated in the planning and analysis of systemic treatment programs in metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019473777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019473777&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19810315)47:6<1369::AID-CNCR2820470622>3.0.CO;2-3

DO - 10.1002/1097-0142(19810315)47:6<1369::AID-CNCR2820470622>3.0.CO;2-3

M3 - Article

C2 - 7226061

AN - SCOPUS:0019473777

VL - 47

SP - 1369

EP - 1376

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -